About coagulation factor ix recombinant human
Human coagulation factor IX replacement
Used for
- Treating bleeding in haemophilia B
- Preventing bleeding in haemophilia B
- Controlling bleeding during surgery in haemophilia B
Usual adult dose
Typically 20–100 IU/kg intravenously for bleeding; repeat dosing depends on severity and factor IX levels. Preventive dosing is individually calculated.
Usual dose in children
Doses are calculated by weight, bleeding severity, and factor IX levels. Children may need higher weight-based doses or more frequent injections.
Common side effects
- Injection-site reactions
- Headache
- Allergic reactions
- Antibodies that reduce treatment effectiveness
Important warnings
- Factor IX Grifols is plasma-derived, not recombinant as listed.
- Severe allergic reactions, including anaphylaxis, can occur.
- Blood clots and factor IX inhibitors can develop.
- Plasma-derived products carry a very small risk of transmitting infections.
Pregnancy
Experience during pregnancy is limited; use requires assessment of benefits and risks.
Breastfeeding
Information during breastfeeding is limited; use requires assessment of benefits and risks.
Interactions
- No established clinically significant medicine interactions.
- Do not mix with other medicines in the same syringe.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.